| 7.76 -0.16 (-2.02%) | 09-01 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.42 |
1-year : | 10.39 |
| Resists | First : | 8.06 |
Second : | 8.9 |
| Pivot price | 7.87  |
|||
| Supports | First : | 6.71 |
Second : | 5.59 |
| MAs | MA(5) : | 7.92 |
MA(20) : | 7.82 |
| MA(100) : | 8.64 |
MA(250) : | 6.76 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37 |
D(3) : | 39.5 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 14.21 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LONA ] has closed above bottom band by 29.6%. Bollinger Bands are 72.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.35 - 8.39 | 8.39 - 8.43 |
| Low: | 7.51 - 7.55 | 7.55 - 7.58 |
| Close: | 7.69 - 7.76 | 7.76 - 7.82 |
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Thu, 07 May 2026
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
Thu, 26 Mar 2026
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Fri, 09 Jan 2026
LeonaBio (LONA) Stock Price, News & Analysis - stocktitan.net
Fri, 09 Jan 2026
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Fri, 09 Jan 2026
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - GlobeNewswire
Tue, 28 Apr 2020
Top Citius Pharmaceuticals (CTXR) Competitors 2026 - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 78.5 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | -23.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.1 % |
| Return on Equity (ttm) | -431.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -62 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0 |
| Price to Book value | 2.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|